Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drug Metabolism And Disposition

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/dmd.114.058339PMID 24875464PMCID PMC4109207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases

  2013influential reference
• Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

  2013influential reference
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)

  2012influential reference
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012influential reference
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012influential reference
• Melanoma brain metastases and vemurafenib: need for further investigation.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Melanoma in the brain: biology and therapeutic options

  2012cited by this paper
• Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice

  2012cited by this paper
• Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

  2012influential reference
• Brain Distribution of Cediranib Is Limited by Active Efflux at the Blood-Brain Barrier

  2012cited by this paper
• Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors

  2011influential reference
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011influential reference
• Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

  2011cited by this paper
• Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

  2011cited by this paper
• Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

  2011influential reference
• Prognostic factors for survival in melanoma patients with brain metastases

  2011cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• Inhibition of mutated BRAF in melanoma.

  2010cited by this paper
• Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds

  2008cited by this paper
• Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

  2008cited by this paper
• Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development

  2007cited by this paper
• Cranial irradiation after surgical excision of brain metastases in melanoma patients

  2006cited by this paper
• Determinants of outcome in melanoma patients with cerebral metastases.

  2004cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

  1998cited by this paper
• Blood–brain barrier

  1977cited by this paper
• DTIC (NSC-45388) in malignant melanoma: a perspective.

  1976cited by this paper
• DTIC (NSC-45388) in malignant melanoma: a perspective.

  1976cited by this paper

• A neuron subtype-specific role of MEK-ERK signaling in axon survival via transcriptional regulation of Nmnat2.

  2026cites this paper
• Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities

  2026cites this paper
• Primary CNS Neuroblastoma, FOXR2-Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review.

  2026cites this paper
• A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma

  2025cites this paper
• Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma

  2025cites this paper
• MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions

  2025cites this paper
• Combination Therapy With Dabrafenib and Trametinib for Langerhans Cell Histiocytosis‐Associated Neurodegenerative Disease

  2025cites this paper
• Targeting Radiation-Induced Glioma-Initiating Cells in Patient-Derived Glioblastoma

  2025influential citation
• The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy.

  2024cites this paper
• The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models

  2024cites this paper
• POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis

  2024cites this paper
• Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution

  2023cites this paper
• Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma

  2023cites this paper
• Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care

  2023cites this paper
• A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

  2023cites this paper
• BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience

  2023cites this paper
• Kinase-Modulated Bioluminescent Indicators Enable Noninvasive Imaging of Drug Activity in the Brain

  2023cites this paper
• Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents

  2022cites this paper
• The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats

  2022cites this paper
• New Directions in the Therapy of Glioblastoma

  2022cites this paper
• ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein

  2022cites this paper
• Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma

  2022cites this paper
• Mechanical Properties of the Extracellular Environment of Human Brain Cells Drive the Effectiveness of Drugs in Fighting Central Nervous System Cancers

  2022cites this paper
• Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?

  2022cites this paper
• Leptomeningeal Metastases: New Opportunities in the Modern Era

  2022cites this paper
• MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus.

  2022cites this paper
• Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy.

  2022cites this paper
• Prevalence and Clinicopathologic Features of Canine Metastatic Melanoma Involving the Central Nervous System: A Retrospective Analysis and Comparative Review

  2022cites this paper
• Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.

  2022cites this paper
• Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier

  2021cites this paper
• Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases

  2021cites this paper
• HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma

  2021cites this paper
• Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

  2021cites this paper
• Osteopontin is highly secreted in the cerebrospinal fluid of patient with posterior pituitary involvement in Langerhans cell histiocytosis

  2020cites this paper
• Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".

  2020cites this paper
• BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

  2020cites this paper
• Management of brain metastases according to molecular subtypes

  2020cites this paper
• Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm

  2020cites this paper
• Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use.

  2019cites this paper
• Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels.

  2019cites this paper
• Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

  2019cites this paper
• Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases

  2019cites this paper
• oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.

  2019cites this paper
• Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality.

  2019cites this paper
• Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy

  2019cites this paper
• CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition

  2019cites this paper
• Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

  2019cites this paper
• MEK/MELK inhibition and blood–brain barrier deficiencies in atypical teratoid/rhabdoid tumors

  2019cites this paper
• Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?

  2019cites this paper
• Central nervous system penetration and efficacy of targeted therapies used in non-small cell lung cancer and melanoma with brain metastases

  2018cites this paper
• Revisiting the role of ABC transporters in multidrug-resistant cancer

  2018cites this paper
• E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

  2018cites this paper
• Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer

  2018cites this paper
• Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma

  2018cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib

  2018cites this paper
• New developments in brain metastases

  2018cites this paper
• Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

  2018cites this paper
• Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

  2018cites this paper
• BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study

  2018cites this paper
• Phosphorylation of Beta-3 adrenergic receptor at serine 247 by ERK MAP kinase drives lipolysis in obese adipocytes

  2018cites this paper
• Toward Precision Medicine in Brain Metastases

  2018cites this paper
• Role of the blood-brain barrier in metastatic disease of the central nervous system.

  2018cites this paper
• The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors

  2018cites this paper
• Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases

  2018cites this paper
• Advances in the systemic treatment of melanoma brain metastases

  2018cites this paper
• Targeted Therapies for Melanoma Brain Metastases

  2017cites this paper
• Rôle du récepteur des xénobiotiques PXR (Pregnane X Receptor) et de ses gènes cibles sur la sensibilité des lignées de cancer de prostate aux inhibiteurs de kinases

  2017cites this paper
• Chapter 23 – Dabrafenib

  2017cites this paper
• Chapter 24 – Trametinib

  2017cites this paper
• Management of intracranial melanomas in the era of precision medicine.

  2017cites this paper
• Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells

  2017cites this paper
• Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901

  2017cites this paper
• Management of intracranial melanomas in the era of precision medicine

  2017cites this paper
• Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.

  2017cites this paper
• Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

  2017cites this paper
• Dabrafenib and trametinib in BRAFV600E mutated glioma.

  2017cites this paper
• Inhibiting Kinases in the CNS

  2017cites this paper
• Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

  2017cites this paper
• Molecular insights into melanoma brain metastases

  2017cites this paper
• Challenges in the Delivery of Therapies to Melanoma Brain Metastases

  2016influential citation
• The ABCG2 Multidrug Transporter

  2016cites this paper
• Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.

  2016cites this paper
• Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

  2016cites this paper
• The Treatment of Melanoma Brain Metastases

  2016cites this paper
• The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.

  2016cites this paper
• Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

  2016cites this paper
• Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors

  2016cites this paper
• Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases

  2016cites this paper
• Brain Metastases from Cutaneous Melanoma

  2016cites this paper
• Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases

  2015cites this paper
• The BRAF kinase domain promotes the development of gliomas in vivo

  2015cites this paper
• Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter

  2015cites this paper
• Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)

  2015cites this paper
• Apical ABC transporters and cancer chemotherapeutic drug disposition.

  2015cites this paper
• Evolving treatment options for melanoma brain metastases.

  2015cites this paper
• Targeted therapies in melanoma.

  2015cites this paper
• Special Section on Transporters in Drug Disposition and Pharmacokinetic Prediction Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases

  year unknowninfluential citation